Research peptide index

AKA Body Protection Compound-157

A synthetic pentadecapeptide derived from a gastric protein; researched for accelerating soft-tissue repair and modulating nitric oxide pathways.

AKA Thymosin Beta-4 fragment

A 17-amino-acid fragment of Thymosin Beta-4 investigated for promoting cellular migration in connective and vascular tissue models.

AKA Mod GRF 1-29

A growth-hormone-releasing-hormone analog researched for its ability to stimulate endogenous pulsatile GH secretion, often paired with a GHRP.

AKA DAC-GRF, CJC-1295 DAC

CJC-1295 conjugated to a Drug Affinity Complex linker that binds serum albumin, extending half-life to roughly eight days and producing a steady GHRH-axis baseline rather than pulsatile peaks.

A selective ghrelin-mimetic pentapeptide investigated for triggering GH release with minimal off-target hormonal effects.

A stabilised GHRH analog researched extensively in HIV-associated lipodystrophy for its visceral-fat-reducing properties.

AKA GHRH(1-29)

The original 1-29 amino-acid fragment of GHRH; researched for restoring pulsatile growth-hormone secretion via direct hypothalamic-pituitary axis stimulation.

A six-amino-acid growth-hormone-releasing peptide investigated for potent acute GH release and ancillary cardiovascular research models.

AKA Long R3 IGF-1

A long-acting IGF-1 analog with an extended N-terminal sequence and an arginine substitution that reduces IGF-binding-protein affinity, producing a substantially longer circulating half-life than native IGF-1.

AKA Mechano Growth Factor, IGF-1Ec

A mechanically-induced splice variant of IGF-1 with a unique C-terminal peptide investigated for activating muscle satellite cells in response to local tissue damage.

AKA Pegylated MGF

A polyethylene-glycol-conjugated MGF variant investigated for circulating an MGF-like signal systemically rather than only at the site of mechanical stress.

AKA ONO-7643

An orally bioavailable selective ghrelin-receptor agonist investigated in cancer-cachexia research-stage trials for appetite stimulation and lean-mass preservation.

A long-acting GLP-1 receptor agonist researched for its role in glucose-dependent insulin secretion and reduced gastric emptying.

A dual GIP and GLP-1 receptor agonist investigated for superior weight and glycaemic outcomes versus selective GLP-1 agonists.

A triple agonist of GIP, GLP-1, and glucagon receptors currently in late-phase research for obesity and metabolic indications.

A fragment of the C-terminus of human GH researched for stimulating lipolysis without affecting blood glucose or IGF-1.

A small-molecule pan-ERR agonist investigated in preclinical models for inducing exercise-mimetic mitochondrial gene expression in muscle and adipose tissue.

A small-molecule selective NNMT inhibitor investigated in preclinical models for reducing methyl-group sequestration in adipose tissue and restoring NAD+/SAM balance.

AKA FTPP, Prohibitin-TP01

A peptidomimetic that homes to prohibitin receptors on white-adipocyte vasculature and triggers localised apoptosis; investigated only in preclinical primate models.

A heptapeptide analog of ACTH fragment 4-10 researched in Russian clinical literature for cognitive and neuroprotective effects.

A synthetic analog of tuftsin researched for anxiolytic effects without sedation or withdrawal in animal and human models.

AKA Delta Sleep-Inducing Peptide

A nonapeptide originally isolated from rabbit cerebral venous blood during slow-wave sleep; investigated for delta-EEG-active sleep induction and circadian research.

AKA Epithalon

A tetrapeptide researched by Khavinson and colleagues for its proposed effects on telomerase activity and circadian regulation.

AKA Nicotinamide adenine dinucleotide

A pyridine-nucleotide coenzyme central to cellular redox reactions and sirtuin signalling; investigated for systemic supplementation of declining endogenous NAD+ pools.

A 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region; investigated as an exercise-mimetic regulator of AMPK and age-related metabolic decline.

AKA Elamipretide, MTP-131

A cell-permeable tetrapeptide that selectively localises to the inner mitochondrial membrane and binds cardiolipin; investigated for preserving cristae structure in mitochondrial disease research.

AKA Copper Peptide

A copper-binding tripeptide investigated for modulating collagen synthesis, antioxidant enzymes, and wound-healing gene expression.

AKA α-MSH(11-13)

A C-terminal tripeptide derivative of α-melanocyte-stimulating hormone investigated for melanocortin-independent anti-inflammatory activity in mucosal and dermal tissue models.

AKA TA-1, Tα1, Zadaxin

A 28-amino-acid peptide originally isolated from the thymus that modulates T-cell maturation and innate immune signalling; investigated as an immune-modulating adjunct.

AKA GSH

A tripeptide (glycine-cysteine-glutamate) that is the dominant intracellular thiol antioxidant; investigated for systemic supplementation of redox capacity.

A cyclic synthetic analog of α-melanocyte-stimulating hormone researched in pigmentation and appetite-suppression models.

AKA Bremelanotide

A cyclic heptapeptide derived from Melanotan II, researched for selective melanocortin-4 receptor activity in sexual-response studies.

A nonapeptide originally isolated from neurohypophyseal extracts; investigated for oxytocin-receptor agonism in affiliative-behaviour and stress-response research.

AKA KP-10

The C-terminal decapeptide fragment of kisspeptin-54; investigated for hypothalamic-pituitary-gonadal axis stimulation via GPR54 receptor agonism.

A four-peptide healing blend pairing BPC-157 and TB-500 with the anti-inflammatory tripeptides GHK-Cu and KPV; investigated as a single-injection convenience format for connective-tissue research.

High-strength variant of the KLOW four-peptide healing blend (BPC-157 + TB-500 + GHK-Cu + KPV at double mass), permitting fewer injections per cycle.

A three-peptide skin and connective-tissue blend leading with GHK-Cu and supplemented with BPC-157 and TB-500; investigated for combined dermal and systemic healing research.

High-strength variant of the GLOW skin and connective-tissue blend (GHK-Cu + BPC-157 + TB-500 at double mass).

A two-peptide healing combo pairing BPC-157 with TB-500 at high mass per vial; the most-studied pairwise healing combination, supplied as a single injection.

The classic short-acting GHRH + GHRP research combination, pre-blended in a single vial for convenience. Pulsatile GH release with a typical pre-sleep timing.

GHRP (Ipamorelin) paired with the long-acting Drug Affinity Complex form of CJC-1295. The DAC component accumulates over weeks toward a steady GHRH baseline; the GHRP provides acute pulses.

A three-component metabolic recomposition stack combining the triple agonist Retatrutide with the mitochondrial peptide MOTS-c and the visceral-fat-targeted GHRH analog Tesamorelin.

The GOD Stack (Retatrutide + MOTS-c + Tesamorelin) combined with KLOW (BPC-157 + TB-500 + GHK-Cu + KPV) — a seven-peptide research blend covering metabolic, mitochondrial and healing axes simultaneously.